Premium
SIE , SIES , GITMO revised guidelines for the management of follicular lymphoma
Author(s) -
Zinzani Pier Luigi,
Marchetti Monia,
Billio Atto,
Barosi Giovanni,
Carella Angelo Michele,
Lazzarino Mario,
Martelli Maurizio,
Rambaldi Alessandro,
Rigacci Luigi,
Tarella Corrado,
Vitolo Umberto,
Tura Sante
Publication year - 2013
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23372
Subject(s) - chemoimmunotherapy , follicular lymphoma , rituximab , medicine , pegfilgrastim , lymphoma , oncology , chemotherapy , neutropenia , febrile neutropenia
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE , SIES , and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III – IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross‐resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy. Am. J. Hematol. 88:185–192, 2013. © 2012 Wiley Periodicals, Inc.